الفهرس 
Acute Myocardial InfarctionOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
Background: Coronary heart disease (CHD) and myocardial infarction (MI) have a significant impact on morbidity and mortality in developed countries. Coronary artery disease results from progressive atherosclerotic plaque development and subsequent thrombus formation.
Aims: To determine plasminogen activator inhibitor -1 antigen level in acute myocardial infarction patients and to evaluate its prognostic impact.
Subjects and Methods: This study was conducted on 30 patients, at the Cardiac intensive care unit of Ain-Shams University Hospitals and the National Heart institute.
Results: AMI who are candidates for PCI ‘group 1’ and 30 healthy individuals as control group ‘group 2’ of matched age and sex. Informed consent was taken from both groups in order to use their data in the study.
Conclusion: PAI-1 increase during the acute phase of AMI. Also PAI-1 level was found to increase in diabetic MI patients dramatically more than non-diabetic MI patients. These levels were found to decrease 6 weeks after MI but not reaching the level of control group, indicating that these patients are still in a hypercoagulable state. PAI-1 could be considered a poor prognostic marker in AMI as it is associated with recurrence of MI.
Recommendations Further clinical studies on wider scale and larger number of cases are recommended. Serial evaluation of PAI-1 level within first 24 hours to study its course.